Option Care Health (Nasdaq: OPCH) lifts Q2 profit and outlines 2026 outlook
Rhea-AI Filing Summary
Option Care Health, Inc. reported second quarter 2026 net revenue of $1,442 million, up 1.9% year over year. GAAP net income was $53.9 million and diluted EPS $0.35, increases of 6.7% and 12.9%. Adjusted EBITDA rose 3.0% to $117.5 million and adjusted diluted EPS grew 9.8% to $0.45.
Operating cash generation increased, with $184 million provided by operating activities in Q2 and $171.5 million in the first half of 2026, compared with $83.1 million a year earlier. The company repurchased $150 million of shares in the quarter. As of June 30, 2026, total assets were $3.38 billion, long-term debt was $1.15 billion and stockholders’ equity was $1.26 billion.
For full-year 2026, Option Care Health expects net revenue of $5.675–$5.775 billion, adjusted EBITDA of $480–$495 million, adjusted diluted EPS of $1.85–$1.92 and at least $320 million of operating cash flow. For third quarter 2026, it anticipates sequential low- to mid-single-digit growth in net revenue and mid-single-digit growth in adjusted EBITDA.
Positive
- Net cash provided by operating activities for the first half of 2026 increased to $171.5 million from $83.1 million in the prior-year period, indicating substantially higher internal cash generation.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Net revenue Q2 2026: $1,442,400 (in thousands)
Net income Q2 2026: $53,913 (in thousands)
Diluted EPS Q2 2026: $0.35
+4 more
7 metrics
Net revenue Q2 2026
$1,442,400 (in thousands)
Consolidated net revenue for the three months ended June 30, 2026
Net income Q2 2026
$53,913 (in thousands)
GAAP net income for the three months ended June 30, 2026
Diluted EPS Q2 2026
$0.35
GAAP diluted earnings per share for the three months ended June 30, 2026
Adjusted EBITDA Q2 2026
$117,482 (in thousands)
Adjusted EBITDA for the three months ended June 30, 2026
Net cash from operating activities H1 2026
$171,485 (in thousands)
Net cash provided by operating activities for the six months ended June 30, 2026
Share repurchases H1 2026
$170,545 (in thousands)
Purchase of company stock and related excise taxes for the six months ended June 30, 2026
Total assets as of June 30, 2026
$3,378,777
Total assets on the condensed consolidated balance sheet at June 30, 2026
Key Terms
Adjusted EBITDA, Adjusted diluted earnings per share, restructuring, acquisition, integration and other, forward-looking statements, +1 more
5 terms
Adjusted EBITDA financial
"The Company is also reporting Adjusted net income, Adjusted EBITDA and Adjusted diluted"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
restructuring, acquisition, integration and other financial
"Restructuring, acquisition, integration and other includes $3,549 and $8,156 of operating"
forward-looking statements regulatory
"This press release contains “forward-looking statements” within the meaning of the safe harbor"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
non-GAAP financial measures financial
"the Company is also reporting Adjusted net income, Adjusted EBITDA and Adjusted diluted EPS, which are non-GAAP financial measures"
Non-GAAP financial measures are numbers companies use to show their financial performance that exclude certain expenses or income. They help investors see how the company might perform without one-time costs or other unusual items, giving a different perspective from official reports. However, since they can be adjusted, they don’t always tell the full story and should be looked at alongside standard financial figures.
Earnings Snapshot
Net revenue: $1,442 million · Guidance included
Second quarter ended June 30, 2026
Net revenue
$1,442 million
up 1.9% year over year
GAAP net income
$53.9 million
up 6.7% year over year
GAAP diluted EPS
$0.35
up 12.9% year over year
Adjusted EBITDA
$117.5 million
up 3.0% year over year
Adjusted diluted EPS
$0.45
up 9.8% year over year
Guidance
For full-year 2026, the company expects net revenue of $5.675–$5.775 billion, adjusted EBITDA of $480–$495 million, adjusted diluted EPS of $1.85–$1.92, and at least $320 million of cash from operating activities, plus low- to mid-single-digit sequential Q3 growth in net revenue and adjusted EBITDA.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
How did Option Care Health (OPCH) perform financially in Q2 2026?
Option Care Health reported Q2 2026 net revenue of $1,442 million, up 1.9% year over year, with GAAP net income of $53.9 million and diluted EPS of $0.35. Adjusted EBITDA was $117.5 million and adjusted diluted EPS was $0.45.
What full-year 2026 guidance did Option Care Health (OPCH) provide?
For 2026, Option Care Health expects net revenue of $5.675–$5.775 billion, adjusted EBITDA of $480–$495 million, adjusted diluted EPS of $1.85–$1.92, and at least $320 million of cash provided by operating activities, outlining its financial outlook for the year.
What does Option Care Health (OPCH)'s June 30, 2026 balance sheet look like?
At June 30, 2026, Option Care Health reported total assets of $3,378,777 thousand, total liabilities of $2,118,879 thousand and stockholders’ equity of $1,259,898 thousand. Long-term debt, net, was $1,152,040 thousand and cash and cash equivalents were $193,767 thousand.
Which non-GAAP measures does Option Care Health (OPCH) use and how are they defined?
Option Care Health reports Adjusted net income, Adjusted EBITDA and Adjusted diluted EPS. These exclude items such as intangible amortization, stock-based compensation, loss on extinguishment of debt and restructuring, acquisition, integration and other expenses, with tax adjustments applied to derive the adjusted results.
What third quarter 2026 outlook did Option Care Health (OPCH) provide?
For Q3 2026, Option Care Health expects sequential net revenue growth in the low to mid single-digits compared to Q2 2026 and sequential adjusted EBITDA growth in the mid single-digits, indicating anticipated quarter-over-quarter expansion in both revenue and profitability measures.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification Number) | ||||||
(Address of principal executive offices)
(312 ) 940-2443
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
| Title of each Class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Item 2.02. Results of Operations and Financial Condition.
On July 29, 2026 , Option Care Health, Inc. issued a press release reporting its second quarter 2026 financial results. A copy of the press release is furnished with this Form 8-K and attached hereto as Exhibit 99.1.
The press release includes certain non-GAAP financial measures described therein. Reconciliation between any non-GAAP financial measures presented and the most directly comparable GAAP financial measures is also provided.
The information in this Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |||||||
| 99.1 | Press release dated July 29, 2026 | |||||||
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Option Care Health, Inc. | |||||||||||
| Date: | By: | /s/ Meenal Sethna | |||||||||
| Meenal Sethna | |||||||||||
| Chief Financial Officer | |||||||||||
Exhibit 99.1
OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026
BANNOCKBURN, IL., July 29, 2026 - Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the second quarter ended June 30, 2026.
Second Quarter 2026 Financial Highlights
(year-over-year comparisons unless otherwise noted)
•Net revenue of $1,442 million, up 1.9%
•GAAP net income of $53.9 million, up 6.7%
•GAAP diluted earnings per share of $0.35, up 12.9%
•Adjusted EBITDA of $117.5 million, up 3.0%
•Adjusted diluted earnings per share of $0.45, up 9.8%
•Cash provided by Q2 operating activities of $184 million
•Repurchased $150 million of outstanding shares in the quarter
John C. Rademacher, Chief Executive Officer, commented, “I’m proud of our team as we delivered strong second quarter results, reflecting solid operational execution and the positive impact of our 2026 strategic initiatives. Looking ahead, our results reinforce our confidence in the underlying fundamentals of the business, but there is still work to do as we further position the company for a sustainable long-term growth trajectory. Given the strength of our clinical platform, significant market opportunities and our operational focus, we believe we are well positioned to achieve our 2026 priorities while creating meaningful value for our patients, partners, and shareholders.”
Updated Full Year and Third Quarter 2026 Financial Guidance
For the full year 2026, Option Care Health expects the following:
•Net revenue of $5.675 billion to $5.775 billion
•Adjusted diluted earnings per share of $1.85 to $1.92
•Adjusted EBITDA of $480 million to $495 million
•Cash provided by operating activities of at least $320 million
For the third quarter 2026, Option Care Health expects the following compared to the second quarter 2026:
•Sequential net revenue growth in the low to mid single-digits
•Sequential Adjusted EBITDA growth in the mid single-digits
Conference Call
Option Care Health will host a conference call to discuss its results on Wednesday, July 29, 2026, at 8:30 a.m. ET. The conference call can be accessed via a live audio webcast that will be available online at investors.optioncarehealth.com. A replay of the call will be available at the same web link for 90 days after the call.
About Option Care Health
Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 8,000 team members, including more than 5,000 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at optioncarehealth.com.
Investor Contact
| Bob Okunski | ||
| Vice President, Investor Relations | ||
| investor.relations@optioncare.com | ||
Forward-Looking Statements - Safe Harbor
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements the Company may make regarding future revenues, future earnings, other future financial results, regulatory developments, market developments, new products and growth strategies and the effects of any of the foregoing on its future results of operations or financial condition.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company's current beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. The Company's actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause the Company's actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: changes in laws, regulations or trade policies applicable to its business model; loss of relationships with managed care organizations and other non-governmental third party payers; changes in the pharmaceutical industry, including limiting or discontinuing research, development, production and marketing of pharmaceuticals compatible with its services; changes in market conditions and receptivity to its services and offerings; and pending and future litigation or potential liability for claims not covered by insurance. For a detailed discussion of the risk factors that could affect its actual results, please refer to the risk factors identified in the Company's SEC reports as filed with the SEC.
Any forward-looking statement made by the Company in this press release is based only on information currently available to it and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Note Regarding Use of Non-GAAP Financial Measures
In addition to reporting financial information in accordance with generally accepted accounting principles (GAAP), the Company is also reporting Adjusted net income, Adjusted EBITDA and Adjusted diluted earnings per share ("EPS"), which are non-GAAP financial measures. These adjusted measures are not measurements of financial performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, EPS, or any other performance measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or a measure of the Company’s liquidity. In addition, the Company's definitions of Adjusted net income, Adjusted EBITDA, and Adjusted diluted EPS may not be comparable to similarly titled non-GAAP financial measures reported by other companies. As defined by the Company: (i) Adjusted net income represents net income before intangible asset amortization expense, stock-based compensation expense, loss on extinguishment of debt, and restructuring, acquisition, integration and other expenses, net of tax adjustments, (ii) Adjusted EBITDA represents net income before net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, and restructuring, acquisition, integration and other expenses, and (iii) Adjusted diluted EPS represents Adjusted net income divided by weighted average common shares outstanding, diluted. As part of restructuring, acquisition, integration and other expenses, the Company may incur significant charges such as the write down of certain long‑lived assets, temporary redundant expenses, professional fees, certain litigation expenses and reserves related to acquired businesses, potential retention and severance costs and potential accelerated payments or termination costs for certain of its contractual obligations. Management believes that these adjusted measures provide useful supplemental information regarding the performance of Option Care Health’s business operations and facilitate comparisons to the Company’s historical operating results. The Company has not reconciled Adjusted EBITDA guidance to net income or Adjusted diluted EPS guidance to GAAP diluted EPS as management believes creation of this reconciliation would not be practicable due to the uncertainty regarding, and potential variability of, material reconciling items. Full reconciliations of each historical adjusted measure to the most comparable GAAP financial measure are set forth below.
Schedule 1
OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS)(UNAUDITED)
| June 30, 2026 | December 31, 2025 | ||||||||||
| ASSETS | |||||||||||
| CURRENT ASSETS: | |||||||||||
| Cash and cash equivalents | $ | 193,767 | $ | 232,624 | |||||||
| Accounts receivable, net | 511,507 | 473,566 | |||||||||
| Inventories | 399,605 | 471,149 | |||||||||
| Prepaid expenses and other current assets | 95,713 | 87,629 | |||||||||
| Total current assets | 1,200,592 | 1,264,968 | |||||||||
| NONCURRENT ASSETS: | |||||||||||
| Property and equipment, net | 140,408 | 139,236 | |||||||||
| Intangible assets, net | 20,229 | 21,897 | |||||||||
| Referral sources, net | 270,410 | 287,281 | |||||||||
| Goodwill | 1,606,743 | 1,606,743 | |||||||||
| Other noncurrent assets | 140,395 | 135,644 | |||||||||
| Total noncurrent assets | 2,178,185 | 2,190,801 | |||||||||
| TOTAL ASSETS | $ | 3,378,777 | $ | 3,455,769 | |||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
| CURRENT LIABILITIES: | |||||||||||
| Accounts payable | $ | 639,767 | $ | 639,829 | |||||||
| Other current liabilities | 179,710 | 189,519 | |||||||||
| Total current liabilities | 819,477 | 829,348 | |||||||||
| NONCURRENT LIABILITIES: | |||||||||||
| Long-term debt, net of discount, deferred financing costs and current portion | 1,152,040 | 1,154,052 | |||||||||
| Other noncurrent liabilities | 147,362 | 145,976 | |||||||||
| Total noncurrent liabilities | 1,299,402 | 1,300,028 | |||||||||
| Total liabilities | 2,118,879 | 2,129,376 | |||||||||
| STOCKHOLDERS’ EQUITY | 1,259,898 | 1,326,393 | |||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 3,378,777 | $ | 3,455,769 | |||||||
Schedule 2
OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)(UNAUDITED)
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| NET REVENUE | $ | 1,442,400 | $ | 1,416,085 | $ | 2,793,054 | $ | 2,749,057 | |||||||||||||||
| COST OF REVENUE | 1,175,149 | 1,147,042 | 2,263,789 | 2,216,962 | |||||||||||||||||||
| GROSS PROFIT | 267,251 | 269,043 | 529,265 | 532,095 | |||||||||||||||||||
| OPERATING COSTS AND EXPENSES: | |||||||||||||||||||||||
| Selling, general and administrative expenses | 161,110 | 167,467 | 331,065 | 330,275 | |||||||||||||||||||
| Restructuring, acquisition, integration and other | 3,549 | 2,625 | 8,156 | 7,935 | |||||||||||||||||||
| Depreciation and amortization expense | 17,452 | 16,241 | 32,359 | 31,987 | |||||||||||||||||||
| Total operating expenses | 182,111 | 186,333 | 371,580 | 370,197 | |||||||||||||||||||
| OPERATING INCOME | 85,140 | 82,710 | 157,685 | 161,898 | |||||||||||||||||||
| OTHER INCOME (EXPENSE): | |||||||||||||||||||||||
| Interest expense, net | (14,020) | (14,447) | (27,324) | (27,678) | |||||||||||||||||||
| Other, net | 2,867 | 598 | 4,629 | (1,803) | |||||||||||||||||||
| Total other (expense) income | (11,153) | (13,849) | (22,695) | (29,481) | |||||||||||||||||||
| INCOME BEFORE INCOME TAXES | 73,987 | 68,861 | 134,990 | 132,417 | |||||||||||||||||||
| INCOME TAX EXPENSE | 20,074 | 18,338 | 35,734 | 35,152 | |||||||||||||||||||
| NET INCOME | $ | 53,913 | $ | 50,523 | $ | 99,256 | $ | 97,265 | |||||||||||||||
| Earnings per share, basic | $ | 0.35 | $ | 0.31 | $ | 0.64 | $ | 0.59 | |||||||||||||||
| Earnings per share, diluted | $ | 0.35 | $ | 0.31 | $ | 0.64 | $ | 0.59 | |||||||||||||||
| Weighted average common shares outstanding, basic | 152,931 | 162,931 | 154,782 | 164,188 | |||||||||||||||||||
| Weighted average common shares outstanding, diluted | 153,485 | 164,133 | 155,772 | 165,402 | |||||||||||||||||||
Schedule 3
OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)(UNAUDITED)
| Six Months Ended June 30, | |||||||||||
| 2026 | 2025 | ||||||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | |||||||||||
| Net income | $ | 99,256 | $ | 97,265 | |||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Depreciation and amortization expense | 34,037 | 33,326 | |||||||||
| Other adjustments | 31,535 | 35,857 | |||||||||
| Changes in operating assets and liabilities: | |||||||||||
| Accounts receivable, net | (37,941) | (61,392) | |||||||||
| Inventories | 71,544 | (12,718) | |||||||||
| Prepaid expenses and other current assets | (9,958) | 17,606 | |||||||||
| Accounts payable | 2,610 | (27,904) | |||||||||
| Accrued compensation and employee benefits | (4,188) | 8,730 | |||||||||
| Other | (15,410) | (7,651) | |||||||||
| Net cash provided by operating activities | 171,485 | 83,119 | |||||||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | |||||||||||
| Acquisition of property and equipment | (20,123) | (18,466) | |||||||||
| Business acquisitions, net of cash acquired | — | (117,247) | |||||||||
| Other investing activities | (877) | — | |||||||||
| Net cash used in investing activities | (21,000) | (135,713) | |||||||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | |||||||||||
| Purchase of company stock and related excise taxes | (170,545) | (152,429) | |||||||||
| Other financing activities | (18,797) | (8,724) | |||||||||
| Net cash used in financing activities | (189,342) | (161,153) | |||||||||
| NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS | (38,857) | (213,747) | |||||||||
| Cash and cash equivalents - beginning of period | 232,624 | 412,565 | |||||||||
| CASH AND CASH EQUIVALENTS - END OF PERIOD | $ | 193,767 | $ | 198,818 | |||||||
Schedule 4
OPTION CARE HEALTH, INC.
QUARTERLY RECONCILIATION BETWEEN GAAP AND NON-GAAP MEASURES
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)(UNAUDITED)
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Net income | $ | 53,913 | $ | 50,523 | $ | 99,256 | $ | 97,265 | |||||||||||||||
| Interest expense, net | 14,020 | 14,447 | 27,324 | 27,678 | |||||||||||||||||||
| Income tax expense | 20,074 | 18,338 | 35,734 | 35,152 | |||||||||||||||||||
| Depreciation and amortization expense | 18,382 | 16,953 | 34,037 | 33,326 | |||||||||||||||||||
| EBITDA | 106,389 | 100,261 | 196,351 | 193,421 | |||||||||||||||||||
| EBITDA adjustments | |||||||||||||||||||||||
| Stock-based incentive compensation expense | 8,382 | 10,712 | 18,581 | 19,513 | |||||||||||||||||||
| Restructuring, acquisition, integration and other (1) | 2,711 | 3,045 | 7,320 | 12,850 | |||||||||||||||||||
| Adjusted EBITDA | $ | 117,482 | $ | 114,018 | $ | 222,252 | $ | 225,784 | |||||||||||||||
| Net income | $ | 53,913 | $ | 50,523 | $ | 99,256 | $ | 97,265 | |||||||||||||||
| Intangible asset amortization expense | 9,269 | 9,297 | 18,539 | 18,394 | |||||||||||||||||||
| Stock-based incentive compensation expense | 8,382 | 10,712 | 18,581 | 19,513 | |||||||||||||||||||
| Restructuring, acquisition, integration and other (1) | 2,711 | 3,045 | 7,320 | 12,850 | |||||||||||||||||||
| Total pre-tax adjustments | 20,362 | 23,054 | 44,440 | 50,757 | |||||||||||||||||||
| Tax adjustments (2) | (5,589) | (6,109) | (11,777) | (13,451) | |||||||||||||||||||
| Adjusted net income | $ | 68,686 | $ | 67,468 | $ | 131,919 | $ | 134,571 | |||||||||||||||
| Earnings per share, diluted | $ | 0.35 | $ | 0.31 | $ | 0.64 | $ | 0.59 | |||||||||||||||
| Adjusted earnings per share, diluted | $ | 0.45 | $ | 0.41 | $ | 0.85 | $ | 0.81 | |||||||||||||||
| Weighted average common shares outstanding, diluted | 153,485 | 164,133 | 155,772 | 165,402 | |||||||||||||||||||
(1) Restructuring, acquisition, integration and other includes $3,549 and $8,156 of operating expenses for the three and six months ended June 30, 2026, respectively. Restructuring, acquisition, integration and other includes $2,625 and $7,935 of operating expenses for the three and six months ended June 30, 2025, respectively.
(2) Tax adjustments for the three and six months ended June 30, 2026 and 2025 includes the estimated income tax effect on non-GAAP adjustments based on the effective tax rate.